http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 13 Oct 2026 08:00:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/MediPharm+Labs+ships+CBD+inhalers+to+Panama+in+first+sale+there/27177337.html <p>MediPharm Labs Corp. (TSX: LABS, OTCQB: MEDIF, FSE: MLZ) has completed its first commercial shipment of CBD metered-dose inhalers to Panama, the Toronto-based company announced, with local distributor Adeiwa Pharma expected to make the products available to patients this month.</p> <p>Adeiwa Pharma will distribute the inhalers through its network of clinics and pharmacies in Panama. The shipment extends MediPharm's international presence to more than 10 countries and regions, including Germany, the United Kingdom, France, Australia, New Zealand, Brazil, and the United States.</p> <p>Panama's medical cannabis framework, established under Law 242 of 2021, allows the National Directorate of Pharmacy and Drugs to authorize http://www.streetinsider.com/Corporate+News/MediPharm+Labs+ships+CBD+inhalers+to+Panama+in+first+sale+there/27177337.html Tue, 13 Oct 2026 08:00:22 -0400 LABS http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Expands+Its+International+Medical+Cannabis+Footprint+with+First+CBD+Metered-Dose+Inhaler+Shipment+to+Panama/27177286.html <p><strong>MediPharm has completed its first shipment to Adeiwa Pharma, which will distribute the product to patients in Panama.</strong></p><p>TORONTO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced its entry into Panama’s medical cannabis market with a first commercial shipment to Adeiwa Pharma. The initial shipment of CBD metered-dose inhalers represents MediPharm’s first sale into the country and extends an international footprint that spans shipments to more than 10 countries and regions, including Germany, the United Kingdom, France, http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Expands+Its+International+Medical+Cannabis+Footprint+with+First+CBD+Metered-Dose+Inhaler+Shipment+to+Panama/27177286.html Tue, 13 Oct 2026 08:00:00 -0400 LABS http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Expands+Its+International+Medical+Cannabis+Footprint+with+First+CBD+Metered-Dose+Inhaler+Shipment+to+Panama/27177286.html <p><strong>MediPharm has completed its first shipment to Adeiwa Pharma, which will distribute the product to patients in Panama.</strong></p><p>TORONTO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced its entry into Panama’s medical cannabis market with a first commercial shipment to Adeiwa Pharma. The initial shipment of CBD metered-dose inhalers represents MediPharm’s first sale into the country and extends an international footprint that spans shipments to more than 10 countries and regions, including Germany, the United Kingdom, France, http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Expands+Its+International+Medical+Cannabis+Footprint+with+First+CBD+Metered-Dose+Inhaler+Shipment+to+Panama/27177286.html Tue, 13 Oct 2026 08:00:00 -0400 LABS http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html <ul type="disc"><li>Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.</li><li>The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial.</li></ul> <p> TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Announces+Positive+Phase+II+LiBBY+Trial+Results+Demonstrating+Significant+Reduction+in+Agitation+Associated+With+Advanced+Alzheimer%E2%80%99s+Disease+and+Dementia/26765424.html Tue, 14 Jul 2026 08:35:00 -0400 A.06822034 A.50216934 LABS MEDIF MLZ O.20026294 O.20026344 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;">Q1 2026 Positive Adjusted EBITDA(1)</li><li style="margin-top:5pt; margin-bottom:5pt;">Net Revenue of $9M with strong gross margins of 37%</li><li style="margin-top:5pt; margin-bottom:5pt;">OPEX decreased 28% in Q1 2026 versus Q4 2025</li><li style="margin-top:5pt; margin-bottom:5pt;">Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities</li><li style="margin-top:5pt; margin-bottom:5pt;">Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET<br/></li></ul> <p align="justify">TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- <strong>MediPharm Labs Corp.</strong> (TSX: <strong>LABS</strong>) (OTCQB: MEDIF) (FSE: MLZ) (&quot;MediPharm&quot;, &quot;MediPharm Labs&quot; or the &quot;Company&quot;), a pharmaceutical company specialized in precision-based cannabinoids, today announced http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html Wed, 13 May 2026 07:30:00 -0400 A.06822034 A.17150087 A.26881573 A.50208593 LABS MEDIF MLZ O.00303771 O.05097238 O.20026344 O.34929518 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;">Q1 2026 Positive Adjusted EBITDA(1)</li><li style="margin-top:5pt; margin-bottom:5pt;">Net Revenue of $9M with strong gross margins of 37%</li><li style="margin-top:5pt; margin-bottom:5pt;">OPEX decreased 28% in Q1 2026 versus Q4 2025</li><li style="margin-top:5pt; margin-bottom:5pt;">Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities</li><li style="margin-top:5pt; margin-bottom:5pt;">Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET<br/></li></ul> <p align="justify">TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- <strong>MediPharm Labs Corp.</strong> (TSX: <strong>LABS</strong>) (OTCQB: MEDIF) (FSE: MLZ) (&quot;MediPharm&quot;, &quot;MediPharm Labs&quot; or the &quot;Company&quot;), a pharmaceutical company specialized in precision-based cannabinoids, today announced http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html Wed, 13 May 2026 07:30:00 -0400 A.06822034 A.17150087 A.26881573 A.50208593 LABS MEDIF MLZ O.00303771 O.05097238 O.20026344 O.34929518 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;">Q1 2026 Positive Adjusted EBITDA(1)</li><li style="margin-top:5pt; margin-bottom:5pt;">Net Revenue of $9M with strong gross margins of 37%</li><li style="margin-top:5pt; margin-bottom:5pt;">OPEX decreased 28% in Q1 2026 versus Q4 2025</li><li style="margin-top:5pt; margin-bottom:5pt;">Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities</li><li style="margin-top:5pt; margin-bottom:5pt;">Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET<br/></li></ul> <p align="justify">TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- <strong>MediPharm Labs Corp.</strong> (TSX: <strong>LABS</strong>) (OTCQB: MEDIF) (FSE: MLZ) (&quot;MediPharm&quot;, &quot;MediPharm Labs&quot; or the &quot;Company&quot;), a pharmaceutical company specialized in precision-based cannabinoids, today announced http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html Wed, 13 May 2026 07:30:00 -0400 A.06822034 A.17150087 A.26881573 A.50208593 LABS MEDIF MLZ O.00303771 O.05097238 O.20026344 O.34929518 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;">Q1 2026 Positive Adjusted EBITDA(1)</li><li style="margin-top:5pt; margin-bottom:5pt;">Net Revenue of $9M with strong gross margins of 37%</li><li style="margin-top:5pt; margin-bottom:5pt;">OPEX decreased 28% in Q1 2026 versus Q4 2025</li><li style="margin-top:5pt; margin-bottom:5pt;">Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities</li><li style="margin-top:5pt; margin-bottom:5pt;">Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET<br/></li></ul> <p align="justify">TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- <strong>MediPharm Labs Corp.</strong> (TSX: <strong>LABS</strong>) (OTCQB: MEDIF) (FSE: MLZ) (&quot;MediPharm&quot;, &quot;MediPharm Labs&quot; or the &quot;Company&quot;), a pharmaceutical company specialized in precision-based cannabinoids, today announced http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html Wed, 13 May 2026 07:30:00 -0400 A.06822034 A.17150087 A.26881573 A.50208593 LABS MEDIF MLZ O.00303771 O.05097238 O.20026344 O.34929518 O.37708452 http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;">Q1 2026 Positive Adjusted EBITDA(1)</li><li style="margin-top:5pt; margin-bottom:5pt;">Net Revenue of $9M with strong gross margins of 37%</li><li style="margin-top:5pt; margin-bottom:5pt;">OPEX decreased 28% in Q1 2026 versus Q4 2025</li><li style="margin-top:5pt; margin-bottom:5pt;">Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities</li><li style="margin-top:5pt; margin-bottom:5pt;">Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET<br/></li></ul> <p align="justify">TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- <strong>MediPharm Labs Corp.</strong> (TSX: <strong>LABS</strong>) (OTCQB: MEDIF) (FSE: MLZ) (&quot;MediPharm&quot;, &quot;MediPharm Labs&quot; or the &quot;Company&quot;), a pharmaceutical company specialized in precision-based cannabinoids, today announced http://www.streetinsider.com/Press+Releases/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html Wed, 13 May 2026 07:30:00 -0400 A.06822034 A.17150087 A.26881573 A.50208593 LABS MEDIF MLZ O.00303771 O.05097238 O.20026344 O.34929518 O.37708452 http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;">Q1 2026 Positive Adjusted EBITDA(1)</li><li style="margin-top:5pt; margin-bottom:5pt;">Net Revenue of $9M with strong gross margins of 37%</li><li style="margin-top:5pt; margin-bottom:5pt;">OPEX decreased 28% in Q1 2026 versus Q4 2025</li><li style="margin-top:5pt; margin-bottom:5pt;">Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities</li><li style="margin-top:5pt; margin-bottom:5pt;">Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET<br/></li></ul> <p align="justify">TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- <strong>MediPharm Labs Corp.</strong> (TSX: <strong>LABS</strong>) (OTCQB: MEDIF) (FSE: MLZ) (&quot;MediPharm&quot;, &quot;MediPharm Labs&quot; or the &quot;Company&quot;), a pharmaceutical company specialized in precision-based cannabinoids, today announced http://www.streetinsider.com/Globe+Newswire/MediPharm+Labs+Reports+First+Quarter+2026+Results+Achieving+Positive+Adjusted+EBITDA/26481728.html Wed, 13 May 2026 07:30:00 -0400 A.06822034 A.17150087 A.26881573 A.50208593 LABS MEDIF MLZ O.00303771 O.05097238 O.20026344 O.34929518 O.37708452